TY - JOUR
T1 - Distribution of lipids in 8,500 men with coronary artery disease
AU - Rubins, Hanna Bloomfield
AU - Robins, Sander J.
AU - Collins, Dorothea
AU - Iranmanesh, Ali
AU - Wilt, Timothy J.
AU - Mann, Douglas
AU - Mayo-Smith, Michael
AU - Faas, Fred H.
AU - Elam, Marshall B.
AU - Rutan, Gale H.
AU - Anderson, James W.
AU - Kashyap, Moti L.
AU - Schectman, Gordon
N1 - Funding Information:
From the Section of Genero Internal Medicine and Department of Medicine, Minneapolis Veterans Affairs Medical Center (VAMC) and the University of Minnesota School of Medicine, Minneapolis, Minnesota; the Section of Lipid Metabolism and Department of Medicine, Boston VAMC and Boston University School of Medicine, Boston, Massachusetts; and the Veterans Affairs (VA) Cooperative Studies Coordinating Center, West Haven VAMC, West Haven, Connecticut. The VA HDL Intervention Trial is funded by the Deportment of Veterans Affairs, VA Cooperative Studies Program, and by a grant from the Parke-Davis Group, Division of the Warner tambert Company, Morris Plains, New Jersey. Manuscript received February 8, 1995; revised manuscript received and accepted April 4, 1995.
PY - 1995/6/15
Y1 - 1995/6/15
N2 - In the present study we measured fasting lipid profiles in over 8,500 community-living men with coronary artery disease (CAD) to determine the distribution of lipid abnormalities in this population: 81% were white and 16% black; mean age 62.9 ± 8 years; mean total cholesterol 214 ± 41 mg/dl; low-density lipoprotein (LDL) cholesterol 140 ± 37 mg/dl; high-density lipoprotein (HDL) cholesterol 39 ± 11 mg/dl; and triglycerides 190 ± 142 mg/dl. After adjusting for age, the only significant difference between blacks and whites was a higher HDL cholesterol in blacks (45 vs 38 mg/dl, p < 0.003). With use of cut points established by the National Cholesterol Education Program, 87% or subjects had high LDL cholesterol (≥100 mg/dl), 38% had low HDL cholesterol (<35 mg/dl), and 33% had high triglycerides (>200 mg/dl). We estimated that 42% of men with CAD would be definite candidates for cholesterol-lowering medication according to the National Cholesterol Education Program guidelines and that 41% of those in whom cholesterol-lowering medication would not be definitely indicated had low levels of HDL cholesterol. We conclude that (1) black men with CAD have substantially higher HDL cholesterol than white men, (2) almost 90% of male patients with CAD are candidates for dietary intervention and >40% may need medications to lower LDL cholesterol, and (3) 40% of patients without a definite indication for cholesterol-lowering medications have low levels of HDL cholesterol.
AB - In the present study we measured fasting lipid profiles in over 8,500 community-living men with coronary artery disease (CAD) to determine the distribution of lipid abnormalities in this population: 81% were white and 16% black; mean age 62.9 ± 8 years; mean total cholesterol 214 ± 41 mg/dl; low-density lipoprotein (LDL) cholesterol 140 ± 37 mg/dl; high-density lipoprotein (HDL) cholesterol 39 ± 11 mg/dl; and triglycerides 190 ± 142 mg/dl. After adjusting for age, the only significant difference between blacks and whites was a higher HDL cholesterol in blacks (45 vs 38 mg/dl, p < 0.003). With use of cut points established by the National Cholesterol Education Program, 87% or subjects had high LDL cholesterol (≥100 mg/dl), 38% had low HDL cholesterol (<35 mg/dl), and 33% had high triglycerides (>200 mg/dl). We estimated that 42% of men with CAD would be definite candidates for cholesterol-lowering medication according to the National Cholesterol Education Program guidelines and that 41% of those in whom cholesterol-lowering medication would not be definitely indicated had low levels of HDL cholesterol. We conclude that (1) black men with CAD have substantially higher HDL cholesterol than white men, (2) almost 90% of male patients with CAD are candidates for dietary intervention and >40% may need medications to lower LDL cholesterol, and (3) 40% of patients without a definite indication for cholesterol-lowering medications have low levels of HDL cholesterol.
UR - http://www.scopus.com/inward/record.url?scp=58149212612&partnerID=8YFLogxK
U2 - 10.1016/S0002-9149(99)80761-9
DO - 10.1016/S0002-9149(99)80761-9
M3 - Article
C2 - 7778538
AN - SCOPUS:58149212612
SN - 0002-9149
VL - 75
SP - 1196
EP - 1201
JO - The American journal of cardiology
JF - The American journal of cardiology
IS - 17
ER -